<p>Kidder Stephen W 在最近向证券交易委员会提交的 13F 文件中表示，在第二季度将其在礼来公司的股份增加了 92.6%。该公司在此期间额外购买了 1,505 股后，持有该公司 3,130 股股票。Kidder Stephen W 在礼来公司的持股在最近一个季度末价值为 2,440,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>5 个推动医疗保健行业大反弹的投资机会</li>
</ul>
<p>其他机构投资者最近也对该公司的持仓进行了调整。Secured Retirement Advisors LLC 在第二季度购买了礼来公司的新股份，价值 1,103,000 美元。NBT Bank N A NY 在第二季度将其在礼来公司的股份增加了 2.2%。NBT Bank N A NY 现在拥有 10,648 股该公司的股票，价值 8,300,000 美元，此前在此期间又购买了 229 股。Abel Hall LLC 在第二季度将其在礼来公司的股份增加了 26.0%。Abel Hall LLC 现在拥有 1,121 股该公司的股票，价值 874,000 美元，此前在上个季度又购买了 231 股。Somerville Kurt F 在第二季度将其在礼来公司的股份增加了 72.2%。Somerville Kurt F 现在拥有 7,242 股该公司的股票，价值 5,645,000 美元，此前在上个季度又购买了 3,036 股。最后，Proffitt &amp; Goodson Inc. 在第二季度将其在礼来公司的持股增加了 2,021.2%。Proffitt &amp; Goodson Inc. 现在拥有 700 股该公司的股票，价值 546,000 美元，此前又购买了 667 股。82.53% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>几家研究公司最近对 LLY 发表了评论。摩根大通将礼来公司的目标股价从 1,100.00 美元下调至 1,050.00 美元，并在 9 月 16 日的研究报告中给予该公司 “增持” 评级。摩根士丹利将礼来公司的目标股价从 1,028.00 美元下调至 1,023.00 美元，并在周五的报告中给予该公司 “增持” 评级。Leerink Partnrs 在 8 月 7 日的研究报告中将礼来公司的评级从 “强力买入” 下调至 “持有”。Cantor Fitzgerald 在 8 月 13 日的研究报告中将礼来公司的目标股价从 975.00 美元下调至 825.00 美元，并对该股票给予 “增持” 评级。最后，瑞银集团在 8 月 8 日的报告中将礼来公司的目标股价从 1,050.00 美元下调至 895.00 美元，并对该公司给予 “买入” 评级。一位分析师对该股票给予了强力买入评级，十四位分析师给予了买入评级，十位分析师给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标股价为 938.94 美元。</p>
<ul>
<li>礼来股票因特朗普关税希望和辉瑞交易而飙升</li>
</ul>
<p><strong>获取我们关于礼来公司的最新研究报告</strong></p>
<h2>礼来公司股票表现</h2>
<p>礼来股票周三开盘价为 844.30 美元。该公司的市值为 799.09 亿美元，市盈率为 55.18，市盈增长比率为 1.18，贝塔系数为 0.47。该公司的 50 日移动平均价格为 736.97 美元，200 日移动平均价格为 766.03 美元。礼来公司的 1 年低点为 623.78 美元，1 年高点为 937.00 美元。该公司的流动比率为 1.28，速动比率为 1.00，债务股本比率为 1.86。</p>
<ul>
<li>特朗普的药品价格削减：对这三家制药巨头的影响是繁荣还是破产</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近于 8 月 7 日发布了季度财报。该公司报告每股收益（EPS）为 6.31 美元，超出市场共识预期的 5.59 美元，超出 0.72 美元。该公司本季度的收入为 155.6 亿美元，而分析师预期为 144.0 亿美元。礼来公司的股本回报率为 92.72%，净利润率为 25.91%。该公司本季度的收入同比增长 37.6%。在去年同期，该公司每股收益为 3.92 美元。礼来公司将其 2025 财年的指导目标设定为 21.750-23.000 EPS。作为一个整体，研究分析师预测礼来公司今年的每股收益将达到 23.48 美元。</p>
<h2>礼来公司的内部买卖</h2>
<p>在其他礼来公司的新闻中，首席执行官 David A. Ricks 于 8 月 12 日星期二购买了 1,632 股该股票。购买的平均价格为每股 644.77 美元，总价值为 1,052,264.64 美元。收购后，首席执行官直接持有该公司 546,601 股股票，价值 352,431,926.77 美元。此次交易使其持股增加了 0.30%。该交易已在向证券交易委员会的备案中披露，可以通过此链接访问。此外，董事 J Erik Fyrwald 于 8 月 12 日星期二购买了 1,565 股礼来公司的股票。购买的平均价格为每股 642.33 美元，总价值为 1,005,246.45 美元。交易完成后，该董事直接持有该公司 74,578 股股票，价值约 47,903,686.74 美元。这代表其持股增加了 2.14%。该购买的披露信息可以在此找到。过去 90 天内，内部人士购买了价值 2,894,841 美元的 4,514 股公司股票。公司内部人士持有该公司 0.14% 的股票。</p>
<h2>礼来公司公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>EA 的 550 亿美元交易引发游戏行业震荡</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>这些是第三季度盈利增长的三个热门行业</li>
<li>经济报告在成功投资策略中的作用</li>
<li>AMD 可能会翻倍——得益于其与 OpenAI 的重磅交易</li>
</ul>
<p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Kidder Stephen W 在第二季度将其在礼来公司（NYSE: LLY）的持股增加了 92.6%，目前持有 3,130 股，价值 244 万美元。其他机构投资者也调整了他们的持仓。分析师对 LLY 的评级不一，目标价格范围从 825 美元到 1,050 美元。该股票开盘价为 844.30 美元，市值为 7990.9 亿美元，市盈率为 55.18。礼来公司报告了强劲的第二季度业绩，超出预期，每股收益为 6.31 美元，收入为 155.6 亿美元，同比增长 37.6%</p>

<p>Kidder Stephen W raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 92.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,130 shares of the company's stock after acquiring an additional 1,505 shares during the period. Kidder Stephen W's holdings in Eli Lilly and Company were worth $2,440,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Kidder Stephen W 在最近向证券交易委员会提交的 13F 文件中表示，在第二季度将其在礼来公司的股份增加了 92.6%。该公司在此期间额外购买了 1,505 股后，持有该公司 3,130 股股票。Kidder Stephen W 在礼来公司的持股在最近一个季度末价值为 2,440,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>5 Healthcare Plays Powering the Sector’s Big Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个推动医疗保健行业大反弹的投资机会</li>
</ul>
</div><p>Other institutional investors have also recently made changes to their positions in the company. Secured Retirement Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $1,103,000. NBT Bank N A NY increased its stake in shares of Eli Lilly and Company by 2.2% during the second quarter. NBT Bank N A NY now owns 10,648 shares of the company's stock worth $8,300,000 after buying an additional 229 shares during the period. Abel Hall LLC increased its stake in Eli Lilly and Company by 26.0% in the second quarter. Abel Hall LLC now owns 1,121 shares of the company's stock valued at $874,000 after purchasing an additional 231 shares during the last quarter. Somerville Kurt F increased its stake in Eli Lilly and Company by 72.2% in the second quarter. Somerville Kurt F now owns 7,242 shares of the company's stock valued at $5,645,000 after purchasing an additional 3,036 shares during the last quarter. Finally, Proffitt &amp; Goodson Inc. boosted its holdings in shares of Eli Lilly and Company by 2,021.2% in the second quarter. Proffitt &amp; Goodson Inc. now owns 700 shares of the company's stock valued at $546,000 after acquiring an additional 667 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者最近也对该公司的持仓进行了调整。Secured Retirement Advisors LLC 在第二季度购买了礼来公司的新股份，价值 1,103,000 美元。NBT Bank N A NY 在第二季度将其在礼来公司的股份增加了 2.2%。NBT Bank N A NY 现在拥有 10,648 股该公司的股票，价值 8,300,000 美元，此前在此期间又购买了 229 股。Abel Hall LLC 在第二季度将其在礼来公司的股份增加了 26.0%。Abel Hall LLC 现在拥有 1,121 股该公司的股票，价值 874,000 美元，此前在上个季度又购买了 231 股。Somerville Kurt F 在第二季度将其在礼来公司的股份增加了 72.2%。Somerville Kurt F 现在拥有 7,242 股该公司的股票，价值 5,645,000 美元，此前在上个季度又购买了 3,036 股。最后，Proffitt &amp; Goodson Inc. 在第二季度将其在礼来公司的持股增加了 2,021.2%。Proffitt &amp; Goodson Inc. 现在拥有 700 股该公司的股票，价值 546,000 美元，此前又购买了 667 股。82.53% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research firms have recently commented on LLY. JPMorgan Chase &amp; Co. reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an &#34;overweight&#34; rating for the company in a research note on Tuesday, September 16th. Morgan Stanley lowered their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an &#34;overweight&#34; rating for the company in a report on Friday. Leerink Partnrs lowered Eli Lilly and Company from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, August 7th. Cantor Fitzgerald cut their target price on Eli Lilly and Company from $975.00 to $825.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, August 13th. Finally, UBS Group lowered their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a &#34;buy&#34; rating for the company in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $938.94.</p>
<div class="lb-trans"><p>几家研究公司最近对 LLY 发表了评论。摩根大通将礼来公司的目标股价从 1,100.00 美元下调至 1,050.00 美元，并在 9 月 16 日的研究报告中给予该公司 “增持” 评级。摩根士丹利将礼来公司的目标股价从 1,028.00 美元下调至 1,023.00 美元，并在周五的报告中给予该公司 “增持” 评级。Leerink Partnrs 在 8 月 7 日的研究报告中将礼来公司的评级从 “强力买入” 下调至 “持有”。Cantor Fitzgerald 在 8 月 13 日的研究报告中将礼来公司的目标股价从 975.00 美元下调至 825.00 美元，并对该股票给予 “增持” 评级。最后，瑞银集团在 8 月 8 日的报告中将礼来公司的目标股价从 1,050.00 美元下调至 895.00 美元，并对该公司给予 “买入” 评级。一位分析师对该股票给予了强力买入评级，十四位分析师给予了买入评级，十位分析师给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标股价为 938.94 美元。</p>
</div><ul>
<li>Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来股票因特朗普关税希望和辉瑞交易而飙升</li>
</ul>
</div><p><strong>Get Our Latest Research Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>获取我们关于礼来公司的最新研究报告</strong></p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>礼来公司股票表现</h2>
</div><p>LLY stock opened at $844.30 on Wednesday. The firm has a market cap of $799.09 billion, a PE ratio of 55.18, a P/E/G ratio of 1.18 and a beta of 0.47. The business's 50-day moving average price is $736.97 and its two-hundred day moving average price is $766.03. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.</p>
<div class="lb-trans"><p>礼来股票周三开盘价为 844.30 美元。该公司的市值为 799.09 亿美元，市盈率为 55.18，市盈增长比率为 1.18，贝塔系数为 0.47。该公司的 50 日移动平均价格为 736.97 美元，200 日移动平均价格为 766.03 美元。礼来公司的 1 年低点为 623.78 美元，1 年高点为 937.00 美元。该公司的流动比率为 1.28，速动比率为 1.00，债务股本比率为 1.86。</p>
</div><ul>
<li>Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普的药品价格削减：对这三家制药巨头的影响是繁荣还是破产</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近于 8 月 7 日发布了季度财报。该公司报告每股收益（EPS）为 6.31 美元，超出市场共识预期的 5.59 美元，超出 0.72 美元。该公司本季度的收入为 155.6 亿美元，而分析师预期为 144.0 亿美元。礼来公司的股本回报率为 92.72%，净利润率为 25.91%。该公司本季度的收入同比增长 37.6%。在去年同期，该公司每股收益为 3.92 美元。礼来公司将其 2025 财年的指导目标设定为 21.750-23.000 EPS。作为一个整体，研究分析师预测礼来公司今年的每股收益将达到 23.48 美元。</p>
</div><h2>Insider Buying and Selling at Eli Lilly and Company</h2>
<div class="lb-trans"><h2>礼来公司的内部买卖</h2>
</div><p>In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock worth $2,894,841 over the last 90 days. Company insiders own 0.14% of the company's stock.</p>
<div class="lb-trans"><p>在其他礼来公司的新闻中，首席执行官 David A. Ricks 于 8 月 12 日星期二购买了 1,632 股该股票。购买的平均价格为每股 644.77 美元，总价值为 1,052,264.64 美元。收购后，首席执行官直接持有该公司 546,601 股股票，价值 352,431,926.77 美元。此次交易使其持股增加了 0.30%。该交易已在向证券交易委员会的备案中披露，可以通过此链接访问。此外，董事 J Erik Fyrwald 于 8 月 12 日星期二购买了 1,565 股礼来公司的股票。购买的平均价格为每股 642.33 美元，总价值为 1,005,246.45 美元。交易完成后，该董事直接持有该公司 74,578 股股票，价值约 47,903,686.74 美元。这代表其持股增加了 2.14%。该购买的披露信息可以在此找到。过去 90 天内，内部人士购买了价值 2,894,841 美元的 4,514 股公司股票。公司内部人士持有该公司 0.14% 的股票。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>These Are the 3 Hottest Sectors for Q3 Earnings Growth</li>
<li>The Role Economic Reports Play in a Successful Investment Strategy</li>
<li>AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>EA 的 550 亿美元交易引发游戏行业震荡</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>这些是第三季度盈利增长的三个热门行业</li>
<li>经济报告在成功投资策略中的作用</li>
<li>AMD 可能会翻倍——得益于其与 OpenAI 的重磅交易</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kidder Stephen W 增持了礼来公司（Eli Lilly）的股票 $LLY